Vowst denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for vowst are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Blue Cross Blue Shield Denied Vowst as "Not FDA-Approved"

Vowst (fecal microbiota, live-jslm) has received FDA approval as a live biotherapeutic product for the prevention of recurrent Clostridioides difficile (C. diff) infection. A "not FDA-approved" denial from BCBS most commonly reflects a system or policy lag — the plan's coverage database has not been updated to recognize the approval, the claim was coded to an indication the label does not cover, or an outdated policy is being applied.

This is one of the most straightforward denials to overturn with proper documentation because the FDA's public record directly contradicts the stated denial reason.

## Why This Denial Is Appealable

• Factual error argument: If Vowst is prescribed for its FDA-approved indication, the denial is based on a factual inaccuracy. Most plan documents require that a drug be FDA-approved for its use to be covered — and here it is.
• ACA §2719 external review: Independent external reviewers have direct access to FDA approval records and regularly overturn these denials. The window to request external review is typically about four months from the internal denial date — do not miss it.
• ERISA §503 (employer plans): Entitles you to all clinical policies and reviewer notes BCBS relied on. Request them in writing with your appeal.
• Expedited review: Available if clinical urgency exists.

## Documentation to Gather

• FDA approval documentation: The FDA's official approval letter and the current prescribing label, both available at DailyMed (search "Vowst"). Print or download with the access date visible.
• BCBS's denial policy: Request the written coverage policy or clinical criteria document BCBS applied. Identify the specific language it used to classify Vowst as unapproved.
• Prescriber medical-necessity letter: The physician should confirm the prescribed indication, confirm it matches the FDA-approved label indication, and document the clinical basis for prescribing.
• C. diff recurrence history: Lab-confirmed episodes with dates, antibiotic courses, and outcomes.

## Criteria-Mapping Approach

| BCBS denial basis | Your response | |---|---| | Drug not FDA-approved | FDA approval letter (dated) + DailyMed label showing approved indication | | Indication outside approved label | Prescriber letter confirming match between prescribed use and label indication | | Outdated coverage policy | Request BCBS update its policy; cite FDA approval date |

## Next Step

File a written internal appeal leading with the FDA approval documentation. Keep it concise and factual: the denial states the drug is not approved; the FDA record shows it is; the denial should be reversed. If BCBS denies the internal appeal, file for external review immediately — this is a particularly strong external-review case because the FDA record is unambiguous.